BR112021014911A2 - Belantamabe mafodotina em combinação com pembrolizumabe para tratamento de câncer - Google Patents
Belantamabe mafodotina em combinação com pembrolizumabe para tratamento de câncerInfo
- Publication number
- BR112021014911A2 BR112021014911A2 BR112021014911A BR112021014911A BR112021014911A2 BR 112021014911 A2 BR112021014911 A2 BR 112021014911A2 BR 112021014911 A BR112021014911 A BR 112021014911A BR 112021014911 A BR112021014911 A BR 112021014911A BR 112021014911 A2 BR112021014911 A2 BR 112021014911A2
- Authority
- BR
- Brazil
- Prior art keywords
- pembrolizumab
- combination
- cancer treatment
- belantamab mafodotin
- belantamab
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 3
- 229940018964 belantamab mafodotin Drugs 0.000 title abstract 2
- 229960002621 pembrolizumab Drugs 0.000 title abstract 2
- 102000025171 antigen binding proteins Human genes 0.000 abstract 2
- 108091000831 antigen binding proteins Proteins 0.000 abstract 2
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 abstract 1
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 abstract 1
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000002519 immonomodulatory effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
Abstract
belantamabe mafodotina em combinação com pembrolizumabe para tratamento de câncer. a presente invenção refere-se a combinações de uma proteína de ligação a antígeno que se liga à bcma com uma proteína de ligação a antígeno que se liga a agentes imunomoduladores, como pd-1 ou 0x40, composições farmacêuticas dos mesmos, usos dos mesmos e métodos de tratamento que compreende a administração de tais combinações, que inclui usos no câncer.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962799857P | 2019-02-01 | 2019-02-01 | |
US201962823298P | 2019-03-25 | 2019-03-25 | |
US201962861008P | 2019-06-13 | 2019-06-13 | |
PCT/US2020/016040 WO2020160365A1 (en) | 2019-02-01 | 2020-01-31 | Belantamab mafodotin in combination with pembrolizumab for treating cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112021014911A2 true BR112021014911A2 (pt) | 2021-11-23 |
Family
ID=69771060
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112021014911A BR112021014911A2 (pt) | 2019-02-01 | 2020-01-31 | Belantamabe mafodotina em combinação com pembrolizumabe para tratamento de câncer |
BR112021014662-8A BR112021014662A2 (pt) | 2019-02-01 | 2020-01-31 | Tratamentos de combinação para o câncer que compreendem belantamab mafodotin e um anticorpo anti ox40 e usos e métodos dos mesmos |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112021014662-8A BR112021014662A2 (pt) | 2019-02-01 | 2020-01-31 | Tratamentos de combinação para o câncer que compreendem belantamab mafodotin e um anticorpo anti ox40 e usos e métodos dos mesmos |
Country Status (9)
Country | Link |
---|---|
US (1) | US20220098303A1 (pt) |
EP (2) | EP3917964A1 (pt) |
JP (2) | JP2022524921A (pt) |
CN (2) | CN113924317A (pt) |
AU (1) | AU2020214412A1 (pt) |
BR (2) | BR112021014911A2 (pt) |
CA (2) | CA3128064A1 (pt) |
MX (1) | MX2021009189A (pt) |
WO (2) | WO2020160365A1 (pt) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112159476B (zh) * | 2020-10-10 | 2022-08-02 | 中国药科大学 | 一种用于多发性骨髓瘤的双特异性抗体及其应用 |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS57106673A (en) | 1980-12-24 | 1982-07-02 | Chugai Pharmaceut Co Ltd | Dibenzo(b,f)(1,4)oxazepin derivative |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US5559235A (en) | 1991-10-29 | 1996-09-24 | Glaxo Wellcome Inc. | Water soluble camptothecin derivatives |
US5342947A (en) | 1992-10-09 | 1994-08-30 | Glaxo Inc. | Preparation of water soluble camptothecin derivatives |
US5681835A (en) | 1994-04-25 | 1997-10-28 | Glaxo Wellcome Inc. | Non-steroidal ligands for the estrogen receptor |
US5491237A (en) | 1994-05-03 | 1996-02-13 | Glaxo Wellcome Inc. | Intermediates in pharmaceutical camptothecin preparation |
GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
GB9716557D0 (en) | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
RS49779B (sr) | 1998-01-12 | 2008-06-05 | Glaxo Group Limited, | Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze |
US6312700B1 (en) | 1998-02-24 | 2001-11-06 | Andrew D. Weinberg | Method for enhancing an antigen specific immune response with OX-40L |
BR122014028365B8 (pt) | 1999-06-25 | 2021-07-06 | Genentech Inc | artigo industrializado compreendendo um primeiro recipiente que compreende uma composição de humab4d5-8 nele contida e um segundo recipiente que compreende uma composição rhumab 2c4 nele contida |
EP1212422B1 (en) | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
CN1305872C (zh) | 2000-06-30 | 2007-03-21 | 葛兰素集团有限公司 | 喹唑啉类化合物的制备方法 |
US20050089932A1 (en) | 2001-04-26 | 2005-04-28 | Avidia Research Institute | Novel proteins with targeted binding |
US20050053973A1 (en) | 2001-04-26 | 2005-03-10 | Avidia Research Institute | Novel proteins with targeted binding |
IL164376A0 (en) | 2002-04-03 | 2005-12-18 | Applied Research Systems | Ox4or binding agents, their preparation and pharmaceutical compositions containing them |
DE60317677T2 (de) | 2002-06-13 | 2008-10-30 | Crucell Holland B.V. | Ox40 (=cd134) rezeptor agonisten und therapeutische verwendung |
EP3287144A1 (en) | 2002-07-03 | 2018-02-28 | ONO Pharmaceutical Co., Ltd. | Immunopotentiating compositions |
CA2543360A1 (en) | 2003-10-24 | 2005-05-06 | Joost A. Kolkman | Ldl receptor class a and egf domain monomers and multimers |
CA2970873C (en) | 2005-05-09 | 2022-05-17 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
EP3222634A1 (en) | 2007-06-18 | 2017-09-27 | Merck Sharp & Dohme B.V. | Antibodies to human programmed death receptor pd-1 |
PT2594590E (pt) | 2007-12-14 | 2015-01-14 | Bristol Myers Squibb Co | Moléculas de ligação ao recetor humano ox40 |
EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
WO2010008726A1 (en) * | 2008-06-16 | 2010-01-21 | Immunogen Inc. | Novel synergistic effects |
KR101573109B1 (ko) | 2009-11-24 | 2015-12-01 | 메디뮨 리미티드 | B7―h1에 대한 표적화된 결합 물질 |
MY171312A (en) | 2010-08-23 | 2019-10-08 | Univ Texas | Anti-ox40 antibodies and methods of using the same |
RS64791B1 (sr) | 2011-05-27 | 2023-11-30 | Glaxo Group Ltd | Bcma (cd269/tnfrsf17) - vezujući proteini |
AU2012299421B2 (en) | 2011-08-23 | 2016-02-04 | Board Of Regents, The University Of Texas System | Anti-OX40 antibodies and methods of using the same |
WO2014055897A2 (en) | 2012-10-04 | 2014-04-10 | Dana-Farber Cancer Institute, Inc. | Human monoclonal anti-pd-l1 antibodies and methods of use |
GB201320729D0 (en) * | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對pd-1的人類抗體 |
AU2016243937A1 (en) * | 2015-04-03 | 2017-11-23 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase for the treatment of cancer |
AU2016308567B2 (en) * | 2015-08-17 | 2022-10-27 | Janssen Biotech, Inc. | Anti-BCMA antibodies, bispecific antigen binding molecules that bind BCMA and CD3, and uses thereof |
EP4015537A1 (en) * | 2015-12-01 | 2022-06-22 | GlaxoSmithKline Intellectual Property Development Limited | Combination treatments and uses and methods thereof |
EP3225253A1 (en) * | 2016-04-01 | 2017-10-04 | Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts | Cancer therapy with an oncolytic virus combined with a checkpoint inhibitor |
US10660909B2 (en) * | 2016-11-17 | 2020-05-26 | Syntrix Biosystems Inc. | Method for treating cancer using chemokine antagonists |
-
2020
- 2020-01-31 AU AU2020214412A patent/AU2020214412A1/en not_active Abandoned
- 2020-01-31 WO PCT/US2020/016040 patent/WO2020160365A1/en unknown
- 2020-01-31 EP EP20712710.1A patent/EP3917964A1/en active Pending
- 2020-01-31 CN CN202080026866.3A patent/CN113924317A/zh active Pending
- 2020-01-31 CA CA3128064A patent/CA3128064A1/en active Pending
- 2020-01-31 US US17/426,695 patent/US20220098303A1/en active Pending
- 2020-01-31 BR BR112021014911A patent/BR112021014911A2/pt not_active Application Discontinuation
- 2020-01-31 BR BR112021014662-8A patent/BR112021014662A2/pt not_active Application Discontinuation
- 2020-01-31 CA CA3128034A patent/CA3128034A1/en active Pending
- 2020-01-31 JP JP2021544712A patent/JP2022524921A/ja active Pending
- 2020-01-31 WO PCT/US2020/016056 patent/WO2020160375A1/en unknown
- 2020-01-31 CN CN202080026857.4A patent/CN113795512A/zh active Pending
- 2020-01-31 MX MX2021009189A patent/MX2021009189A/es unknown
- 2020-01-31 EP EP20709818.7A patent/EP3917963A1/en active Pending
- 2020-01-31 JP JP2021544527A patent/JP2022523100A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2020160375A9 (en) | 2020-10-22 |
WO2020160365A1 (en) | 2020-08-06 |
US20220098303A1 (en) | 2022-03-31 |
CN113795512A (zh) | 2021-12-14 |
JP2022524921A (ja) | 2022-05-11 |
CA3128034A1 (en) | 2020-08-06 |
WO2020160375A1 (en) | 2020-08-06 |
EP3917963A1 (en) | 2021-12-08 |
EP3917964A1 (en) | 2021-12-08 |
CA3128064A1 (en) | 2020-08-06 |
CN113924317A (zh) | 2022-01-11 |
MX2021009189A (es) | 2021-11-12 |
AU2020214412A1 (en) | 2021-08-12 |
BR112021014662A2 (pt) | 2021-09-21 |
JP2022523100A (ja) | 2022-04-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1123397T1 (el) | Συνθεσεις που περιλαμβανουν συνδυασμο ιπιλιμουμαμπης και νιβολουμαμπης | |
BR112018011228A2 (pt) | tratamentos de combinação e seus usos e métodos | |
BR112018011781A2 (pt) | molécula biespecífica possuindo um ou mais sítios de ligação a epítopo capazes de ligação imunoespecífica a (um) epítopo(s) de pd-1 e um ou mais sítios de ligação a epítopo capazes de ligação imunoespecífica a (um) epítopo(s) de ctla-4, e composição farmacêutica | |
CY1119766T1 (el) | Νεοι ρυθμιστες κινασης βενζοπυρανιου | |
BR112022002442A2 (pt) | Terapias de imuno-oncologia com conjugados de il-2 | |
BR112018012164A2 (pt) | anticorpos neutralizantes do vírus da imunodeficiência humana | |
BR112018000542A2 (pt) | composições de irna de transtirretina (ttr) e métodos de uso das mesmas para o tratamento ou prevenção de doenças associadas à ttr | |
BR112019016497A2 (pt) | 2-heteroaril-3-oxo-2,3-di-hidropiridazina-4-carboxamidas para o tratamento de câncer. | |
BR112018074185A2 (pt) | 3-oxo-2,6-difenil-2,3-di-hidropiridazina-4-carboxamidas | |
BR112017017727A2 (pt) | heterociclos bicíclicos como inibidores de fgfr4 | |
BR112018074978A2 (pt) | anticorpos para alfa-sinucleína e usos dos mesmos | |
BR112014021498A2 (pt) | composto, composição e método para tratar uma doença associada com formação de dna circular covalentemente fechado | |
BR112018013084A2 (pt) | tratamentos de combinação compreendendo a administração de imidazopirazinonas | |
BR112018072545A2 (pt) | inibidores da arginase e suas aplicações terapêuticas | |
BR112019017403A2 (pt) | composições e métodos para o tratamento de câncer | |
TR201901077T4 (tr) | Kanser Veya Enfeksiyon Tedavisine Yönelik Birleşik Preparasyonlar | |
BR112018016968A2 (pt) | derivados de carboxamida úteis como inibidores de rsk | |
BR112021017350A2 (pt) | Combinação de conjugado de anticorpo-derivado de pirrolobenzodiazepina e inibidor de parp | |
CY1122968T1 (el) | Φαρμακευτικη συνθεση η οποια περιλαμβανει μια ενωση διαμινο-ετεροκυκλικου καρβοξαμιδιου ως δραστικο συστατικο | |
BR112019006887A2 (pt) | ativadores do fluxo autofágico e fosfolipase d e depuração de agregado proteico, incluindo tau e tratamento de proteinopatias | |
EP4299126A3 (en) | Peripherally restricted gaba positive allosteric modulators for the treatment of irritable bowel syndrome and other ailments of the peripheral nervous system | |
BR112022003335A2 (pt) | Conjugados de il-2 e métodos de uso para tratar doenças autoimunes | |
BR112016001781A2 (pt) | inibidores de rorc2 e métodos de uso dos mesmos | |
BR112016030730A8 (pt) | composto | |
BR112017025031A2 (pt) | composições farmacêuticas de liberação prolongada de levetiracetam |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |